Get access

Pegylated liposomal doxorubicin for multiple myeloma

  • Protocol
  • Intervention

Authors

  • Zhiyong Zeng,

    Corresponding author
    1. The First Affiliated Hospital of Fujian Medical University, Department of Hematology and Rheumatology, Fuzhou, Fujian Province, China
    • Zhiyong Zeng, Department of Hematology and Rheumatology, The First Affiliated Hospital of Fujian Medical University, Chating, Fuzhou, Fujian Province, 350005, China. zengzhiyong049@163.com.

    Search for more papers by this author
  • Junmin Chen,

    1. The First Affiliated Hospital of Fujian Medical University, Department of Hematology and Rheumatology, Fuzhou, Fujian Province, China
    Search for more papers by this author
  • Junfang Lin,

    1. The First Affiliated Hospital of Fujian Medical University, Department of Hematology and Rheumatology, Fuzhou, Fujian Province, China
    Search for more papers by this author
  • Shengnan Wang

    1. The First Affiliated Hospital of Fujian Medical University, Department of Hematology and Rheumatology, Fuzhou, Fujian Province, China
    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the clinical efficacy and safety of pegylated liposomal doxorubicin in patients with MM.

Get access to the full text of this article